Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Rotigotine: Dopamine D2/D3 Receptor Agonist for Parkinson...

    2026-03-16

    Rotigotine: Dopamine D2/D3 Receptor Agonist for Parkinson’s Disease Research

    Executive Summary: Rotigotine is a synthetic dopamine receptor agonist with nanomolar affinity for D2 (Ki = 13 nM) and D3 (Ki = 0.71 nM) receptors, enabling precise modulation of dopaminergic pathways in experimental models (Bertaina-Anglade et al., 2006). It exhibits significant antiparkinsonian activity and is highly valued in both behavioral and cell-based neuroscience assays (APExBIO). Rotigotine also binds with notable affinity to 5-HT1A and adrenergic α2B receptors, broadening its relevance in neuropharmacological research. Its crystalline solid form ensures robust solubility in DMSO (≥58 mg/mL) and ethanol (≥25.25 mg/mL), but it is insoluble in water and should be stored at -20°C. The compound’s research-grade purity (≥98%) and well-documented stability parameters support reproducibility across diverse experimental protocols (APExBIO).

    Biological Rationale

    Rotigotine is a non-ergoline dopamine receptor agonist, structurally designed to engage D2 and D3 subtypes with high selectivity. It is widely used to model Parkinson’s disease (PD) and related neuropsychiatric conditions with dopaminergic involvement. Depression is a common comorbidity in PD, affecting 25–40% of patients (Bertaina-Anglade et al., 2006). Overlapping symptoms such as psychomotor retardation and fatigue complicate differential diagnosis between PD and depressive disorders. Rotigotine’s ability to modulate both motor and mood-related dopaminergic circuits makes it a valuable probe for mechanistic and translational research on PD and associated mood disturbances.

    Mechanism of Action of Rotigotine

    Rotigotine acts as a full agonist at dopamine D2 and D3 receptors. The affinity constants are Ki = 13 nM for D2 and Ki = 0.71 nM for D3, indicating high potency at physiologically relevant concentrations (APExBIO). It also shows significant interaction with 5-HT1A and adrenergic α2B receptors, which may contribute to its neuropsychiatric and antiparkinsonian effects. By stimulating dopaminergic pathways, particularly in the nigrostriatal and mesolimbic systems, Rotigotine restores or modulates neurotransmission impaired in PD models. In animal studies, higher doses (≥5 mg/kg) increase spontaneous locomotor activity, while lower doses selectively reverse depressive-like behaviors without nonspecific hyperactivity (Bertaina-Anglade et al., 2006).

    Evidence & Benchmarks

    • Rotigotine (5 mg/kg, 3–5 days) increases spontaneous motor activity in rats, confirming robust dopaminergic activation (Bertaina-Anglade et al., 2006).
    • Doses of 0.5, 1, and 5 mg/kg/day (5 days) reverse learned helplessness in rats, reducing escape failures by day 3–5 (Bertaina-Anglade et al., 2006).
    • Rotigotine enhances mobility in the forced swim test at 5 mg/kg, a validated model of antidepressant activity (Bertaina-Anglade et al., 2006).
    • It displays a U-shaped dose–response in reversing hyperactivity in olfactory bulbectomized rats after 14 days (0.3 mg/kg every 2 days) (Bertaina-Anglade et al., 2006).
    • Rotigotine’s physicochemical profile: molecular weight 315.47, formula C19H25NOS, crystalline solid; DMSO solubility ≥58 mg/mL; ethanol solubility ≥25.25 mg/mL; water insoluble (APExBIO).

    This article extends the discussion in "Rotigotine: Dopamine D2/D3 Receptor Agonist for Parkinson..." by providing direct evidence from peer-reviewed benchmarks and updated solubility and stability parameters.

    For further mechanistic insights and strategic guidance, see "Rotigotine: Advancing Dopaminergic Research from Mechanis...", which focuses on translational workflows, whereas this dossier details quantitative model outcomes and compound handling.

    Applications, Limits & Misconceptions

    Rotigotine is primarily utilized in experimental models of Parkinson’s disease, depression, and dopaminergic dysfunction. Its high receptor selectivity allows dissection of dopaminergic signaling in both behavioral and cell-based assays. Researchers use it to:

    • Model motor symptoms and non-motor comorbidities (e.g., depression) in PD.
    • Probe dopaminergic signaling in mechanistic neurobiology.
    • Screen and validate novel neuroactive compounds via cell-based receptor assays.
    • Benchmark antiparkinsonian and antidepressant activity in rodent models.

    Common Pitfalls or Misconceptions

    • Not a clinical or diagnostic agent: Rotigotine from APExBIO is for research use only; it is not approved for medical or diagnostic applications (APExBIO).
    • Limited water solubility: Rotigotine is insoluble in water; improper solvent selection can lead to assay failure.
    • Long-term solution instability: Solutions degrade over time; prepare fresh aliquots and use promptly (APExBIO).
    • High-dose behavioral confounds: Doses ≥5 mg/kg may cause nonspecific hyperactivity, complicating interpretation in behavioral paradigms (Bertaina-Anglade et al., 2006).
    • Species-dependent pharmacokinetics: Transdermal delivery is not feasible in rodents due to rapid hair growth and poor skin permeation (Bertaina-Anglade et al., 2006).

    For a practical guide to protocol optimization and troubleshooting, see "Rotigotine (SKU A3776): Reliable Dopamine Agonist for Par...". This dossier clarifies compound limitations and expands on solution handling parameters.

    Workflow Integration & Parameters

    Rotigotine is supplied as a crystalline solid with ≥98% purity (SKU A3776, APExBIO). Prepare stock solutions in DMSO (≥58 mg/mL) or ethanol (≥25.25 mg/mL). Avoid water as a solvent. Store dry powder at -20°C and protect solutions from repeated freeze-thaw cycles. For cell-based dopamine receptor activity assays, titrate concentrations to match the receptor subtype's EC50 or Ki values (D2: 13 nM; D3: 0.71 nM). In animal models, behavioral endpoints are dose-dependent; for example, 1 mg/kg/day is effective in reversing learned helplessness within 5 days (Bertaina-Anglade et al., 2006).

    For strategic workflow recommendations and troubleshooting, "Rotigotine: Dopamine D2/D3 Receptor Agonist for Parkinson..." offers protocol validation support, whereas this dossier focuses on integrating up-to-date compound handling and benchmarking data.

    Conclusion & Outlook

    Rotigotine is a rigorously characterized dopamine D2/D3 receptor agonist, enabling advanced research into Parkinson’s disease and dopaminergic signaling. Its validated antiparkinsonian and antidepressant activities, along with robust receptor selectivity, make it indispensable for both mechanistic and translational neuroscience workflows. Researchers are encouraged to leverage Rotigotine’s high purity and stability, as supplied by APExBIO, to ensure reproducibility and precision in experimental designs. For further details and ordering information, visit the Rotigotine product page.